PMV Pharmaceuticals (PMVP) Competitors $1.09 -0.04 (-3.54%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PMVP vs. ESPR, VYGR, DERM, OGI, DMAC, CYBN, FDMT, SLN, TLSA, and INMBShould you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Esperion Therapeutics (ESPR), Voyager Therapeutics (VYGR), Journey Medical (DERM), Organigram (OGI), DiaMedica Therapeutics (DMAC), Cybin (CYBN), 4D Molecular Therapeutics (FDMT), Silence Therapeutics (SLN), Tiziana Life Sciences (TLSA), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. PMV Pharmaceuticals vs. Its Competitors Esperion Therapeutics Voyager Therapeutics Journey Medical Organigram DiaMedica Therapeutics Cybin 4D Molecular Therapeutics Silence Therapeutics Tiziana Life Sciences INmune Bio PMV Pharmaceuticals (NASDAQ:PMVP) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, community ranking, dividends, valuation and analyst recommendations. Is PMVP or ESPR more profitable? PMV Pharmaceuticals has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -29.37%. Esperion Therapeutics' return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PMV PharmaceuticalsN/A -24.20% -21.67% Esperion Therapeutics -29.37%N/A -10.77% Does the MarketBeat Community believe in PMVP or ESPR? Esperion Therapeutics received 607 more outperform votes than PMV Pharmaceuticals when rated by MarketBeat users. Likewise, 70.27% of users gave Esperion Therapeutics an outperform vote while only 63.16% of users gave PMV Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPMV PharmaceuticalsOutperform Votes2463.16% Underperform Votes1436.84% Esperion TherapeuticsOutperform Votes63170.27% Underperform Votes26729.73% Which has more volatility & risk, PMVP or ESPR? PMV Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Do institutionals & insiders have more ownership in PMVP or ESPR? 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate PMVP or ESPR? PMV Pharmaceuticals currently has a consensus price target of $5.50, indicating a potential upside of 404.59%. Esperion Therapeutics has a consensus price target of $6.25, indicating a potential upside of 420.83%. Given Esperion Therapeutics' higher possible upside, analysts clearly believe Esperion Therapeutics is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Esperion Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation & earnings, PMVP or ESPR? PMV Pharmaceuticals has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPMV PharmaceuticalsN/AN/A-$68.96M-$1.18-0.92Esperion Therapeutics$259.57M0.92-$209.25M-$0.80-1.50 Does the media prefer PMVP or ESPR? In the previous week, Esperion Therapeutics had 14 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 15 mentions for Esperion Therapeutics and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.89 beat Esperion Therapeutics' score of 1.03 indicating that PMV Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment PMV Pharmaceuticals Very Positive Esperion Therapeutics Positive SummaryEsperion Therapeutics beats PMV Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get PMV Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PMVP vs. The Competition Export to ExcelMetricPMV PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.63M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-1.098.6727.1719.96Price / SalesN/A262.53410.96157.63Price / CashN/A65.8538.2534.64Price / Book0.256.597.064.69Net Income-$68.96M$143.75M$3.23B$248.14M7 Day Performance12.37%0.82%0.77%0.95%1 Month Performance27.90%12.09%9.67%5.74%1 Year Performance-37.36%4.46%32.02%14.73% PMV Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PMVPPMV Pharmaceuticals2.4556 of 5 stars$1.09-3.5%$5.50+404.6%-38.4%$56.63MN/A-1.0950Positive NewsESPREsperion Therapeutics4.1032 of 5 stars$0.92+8.1%$6.25+580.4%-58.5%$182.07M$259.57M-1.44200Positive NewsAnalyst RevisionVYGRVoyager Therapeutics4.4301 of 5 stars$3.29+20.1%$13.39+307.0%-58.5%$182.06M$66.96M4.63100Trending NewsAnalyst RevisionHigh Trading VolumeDERMJourney Medical2.3354 of 5 stars$7.81-3.1%$9.88+26.4%+17.3%$181.94M$56.24M-8.3190Positive NewsShort Interest ↑High Trading VolumeOGIOrganigram0.6322 of 5 stars$1.31-3.0%N/A-8.7%$180.74M$194.09M-3.45860News CoveragePositive NewsDMACDiaMedica Therapeutics1.3513 of 5 stars$4.17+1.5%$8.00+91.8%+55.4%$178.82MN/A-7.4520Short Interest ↑CYBNCybin3.0243 of 5 stars$8.10+1.8%$86.00+961.7%N/A$173.96MN/A-1.8550News CoverageAnalyst RevisionFDMT4D Molecular Therapeutics2.9327 of 5 stars$3.75+3.6%$29.56+688.1%-81.3%$173.72M$23K-1.32120Analyst ForecastAnalyst RevisionSLNSilence Therapeutics3.0962 of 5 stars$5.73-1.9%$33.83+490.5%-73.1%$171.50M$27.70M-3.65100Positive NewsTLSATiziana Life Sciences1.223 of 5 stars$1.44+5.9%N/A+74.0%$168.26MN/A0.008Gap UpINMBINmune Bio2.0955 of 5 stars$7.19-2.6%$22.80+217.1%-9.5%$165.26M$50K-3.3010News CoveragePositive NewsGap Up Related Companies and Tools Related Companies Esperion Therapeutics Alternatives Voyager Therapeutics Alternatives Journey Medical Alternatives Organigram Alternatives DiaMedica Therapeutics Alternatives Cybin Alternatives 4D Molecular Therapeutics Alternatives Silence Therapeutics Alternatives Tiziana Life Sciences Alternatives INmune Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PMVP) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PMV Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PMV Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PMVP Stock Free PMVP Stock Alerts